NCT03837509 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 15
- units
- Participants
- groups
- description
- In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG000
- title
- Phase 1: INCB001158 75 mg BID + Daratumumab
- description
- In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG001
- title
- Phase 1: INCB001158 100 mg BID + Daratumumab
- description
- In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG002
- title
- Phase 2: INCB001158 100 mg BID + Daratumumab
- description
- In Part 1 of Phase 2, participants received daratumumb 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.
- id
- BG003
- title
- Phase 2: Daratumumab Monotherapy; Cross Over to INCB001158 + Daratumumab
- description
- In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.
- id
- BG004
- title
- Phase 2: INCB001158 Monotherapy; Cross Over to INCB001158 + Daratumumab
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.70
- value
- 65.0
- group Id
- BG001
- spread
- 9.83
- value
- 68.0
- group Id
- BG002
- spread
- 12.73
- value
- 67.0
- comment
- To protect participant privacy, a mean age and standard deviation are not reported for a single participant.
- group Id
- BG003
- spread
- NA
- value
- NA
- group Id
- BG004
- spread
- 19.09
- value
- 71.5
- group Id
- BG005
- spread
- 10.59
- value
- 67.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- comment
- To protect participant privacy, sex is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- comment
- To protect participant privacy, sex is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 2
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 1
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 1
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 2
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 15
- units
- Participants
- groups
- description
- In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG000
- title
- Phase 1: INCB001158 75 mg BID + Daratumumab
- description
- In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG001
- title
- Phase 1: INCB001158 100 mg BID + Daratumumab
- description
- In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.
- id
- BG002
- title
- Phase 2: INCB001158 100 mg BID + Daratumumab
- description
- In Part 1 of Phase 2, participants received daratumumb 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.
- id
- BG003
- title
- Phase 2: Daratumumab Monotherapy; Cross Over to INCB001158 + Daratumumab
- description
- In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.
- id
- BG004
- title
- Phase 2: INCB001158 Monotherapy; Cross Over to INCB001158 + Daratumumab
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.70
- value
- 65.0
- group Id
- BG001
- spread
- 9.83
- value
- 68.0
- group Id
- BG002
- spread
- 12.73
- value
- 67.0
- comment
- To protect participant privacy, a mean age and standard deviation are not reported for a single participant.
- group Id
- BG003
- spread
- NA
- value
- NA
- group Id
- BG004
- spread
- 19.09
- value
- 71.5
- group Id
- BG005
- spread
- 10.59
- value
- 67.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- comment
- To protect participant privacy, sex is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- comment
- To protect participant privacy, sex is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 2
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 1
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 1
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, ethnicity is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 2
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- comment
- To protect participant privacy, race is not reported for a single participant.
- group Id
- BG003
- value
- NA
- group Id
- BG004
- value
- 0
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG005
- value
- NA
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle